ArticleMethods in molecular biology (Clifton, N.J.)2014
Modulation of autoimmune diseases by iPS cells.
Article in Methods in molecular biology (Clifton, N.J.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Alternating 2D and 3D culture reduces cell size and extends the lifespan of placenta-derived mesenchymal stem cells.Frontiers in bioengineering and biotechnology · 2025Article
- Research progress of autoimmune diseases based on induced pluripotent stem cells.Frontiers in immunology · 2024Review
- Stem cell-derived tissue-associated regulatory T cells ameliorate the development of autoimmunity.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Autoimmune disease is typically caused by the activated self-reacted immune cells. The mainstream treatment to autoimmune disorders is composed of different mechanisms of immunosuppression. In recent years, a new subtype of T cells called regulatory T (Treg) cells have been identified to maintain the immune homeostasis in terms of suppressing the activated immune components. According to this discovery, it is suggested that treating autoimmune patients by supplementing Treg cells would be a good choice. However, due to their natural scarcity, it is difficult to isolate a desired number of Treg for this therapeutical approach. Here, we report that by using stem cells, especially the induced pluripotent stem (iPS) cells, we are able to generate a significant amount of Treg cells for the autoimmune prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.